Duactin

Quick links to important sections

Duactin

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Duactin

What is Duactin?

Duactin is a fixed-dose combination medication formulated to manage specific gastrointestinal symptoms. It contains two active pharmacological agents: famotidine and sucralfate. By combining these components, the medication addresses gastric acid production while simultaneously providing a protective barrier for the mucosal lining of the digestive tract.

Components and Mechanism of Action

The efficacy of Duactin is derived from the distinct yet complementary functions of its two primary ingredients:

  • Famotidine: This component belongs to a class of drugs known as H2-receptor antagonists. It works by blocking the histamine receptors in the stomach lining, which results in a significant reduction in the volume and concentration of gastric acid secreted by the body.
  • Sucralfate: This ingredient acts as a local mucosal adherent. In the presence of gastric acid, sucralfate undergoes a chemical reaction to form a paste-like substance. This substance adheres to the surface of gastric and duodenal ulcers or inflamed tissue, creating a physical shield against further irritation from acid, pepsin, and bile salts.

Therapeutic Purpose

Duactin is primarily utilized in the treatment of conditions characterized by excessive acid production or damage to the upper gastrointestinal lining. This includes the management of active duodenal ulcers and the treatment of benign gastric ulcers. The combination therapy is designed to alleviate pain and discomfort by lowering acidity levels and promoting an environment conducive to the natural healing of the mucosal tissue.

Regulatory References

  1. MedlinePlus - Amlodipine

What side effects are possible with Duactin?

Possible Side Effects and Safety Information for Duactin

The safety profile of Duactin is formally documented in government regulatory files based on clinical trial data and post-marketing surveillance. The information below reflects the risks documented in official drug labels, categorized by frequency and system-organ class.

Serious and Clinically Significant Adverse Reactions

Official labels contain Boxed Warnings (the most serious type of warning) and specific precautions detailing risks that may be disabling, potentially irreversible, or life-threatening. These typically include:

  • Tendinitis and Tendon Rupture: Inflammation or tearing of tendons, including the Achilles tendon. This risk is increased in geriatric patients, those taking corticosteroids, or organ transplant recipients.
  • Peripheral Neuropathy: Symptoms of tingling, numbness, or pain in the extremities, which can occur rapidly and may become permanent.
  • Central Nervous System Effects: Changes in mood, thinking, and behavior, including anxiety, confusion, hallucinations, and suicidal ideations.
  • Hypersensitivity: Severe allergic reactions, including anaphylaxis, sometimes occurring after the first dose.

Common Adverse Reactions

Adverse reactions classified as Common (occurring in 1% to 10% of patients) or Very Common (ge10%) frequently involve the Gastrointestinal System and the Nervous System. These may include nausea, diarrhea, vomiting, headache, or dizziness.


Restrictions and Monitoring

Duactin may be Contraindicated (must not be used) in patients with a history of hypersensitivity to the drug or related compounds. The official label specifies situations where the risks may outweigh the benefits for patients with certain uncomplicated infections, suggesting its use should be reserved for those without alternative treatment options.

Safety Monitoring Notes: Due to the risk of organ-specific adverse events, the regulatory label requires clinicians to monitor for signs of serious reactions, including those affecting the cardiac, hepatic, and renal systems. All patients are advised to read the provided Medication Guide for complete risk information.

Overdose and Emergency Response

Overdose and when to seek help

The following section summarizes the officially documented overdose information for Duactin (Amlodipine) from government regulatory sources.

Overdose scope

Documented overdose presentations: Overdose may result in marked hypotension (low blood pressure) due to excessive peripheral vasodilation, potentially accompanied by reflex tachycardia (rapid heart rate) and fainting (syncope).

Physiological systems affected (as stated in label): The cardiovascular system.

Dose-related or exposure-related factors (if applicable): The drug’s long elimination half-life necessitates extended clinical monitoring.

Population-specific overdose notes (if applicable): Patients with severe aortic stenosis are noted to have an increased risk of severe hypotension following overdose.

Emergency-response statements (as written in official documents): Seek emergency medical attention immediately.

When immediate medical help is required (label-derived phrasing only): Medical help is required for profound hypotension and signs of shock, which are classified as life-threatening outcomes.

Overdose classifications (high-level)

Severity classification (as defined in official documents): The condition can escalate to a severe or life-threatening state.

Overdose-context constraints (as defined in official documents): No specific antidote is known. Hemodialysis is not likely to be of benefit.

Resulting overdose structure

Official overdose statements:

  • Active cardiac and respiratory monitoring must be initiated immediately.
  • Management is symptomatic and supportive treatment, including elevation of the extremities and judicious administration of fluids.
  • If hypotension is unresponsive, the use of vasopressors may be necessary.
  • Gastric decontamination (e.g., activated charcoal) may be warranted.
  • Overnight hospital stay may be required for continuous observation.

Connection to the overall overdose profile: Regulatory documents define the overdose profile based on an excessive extension of the drug's primary action, leading to marked hypotension. Official guidance mandates immediate medical care and defines a strict structure for management, focusing on cardiovascular support and extended monitoring due to the long duration of effects, while explicitly stating that no specific antidote is known.

Therapeutic Uses of Duactin

The active ingredient, Amlodipine, is used to manage conditions associated with cardiovascular and vascular stress. The main therapeutic goals are related to chronic diseases and symptom management.


What Duactin Treats: Main Uses and Benefits

Amlodipine is commonly used in conditions that require ongoing symptomatic support, such as Essential Hypertension, Angina Pectoris, and Coronary Artery Disease (CAD). This application is considered relevant in conditions marked by increased physiological stress. It is relevant for managing symptom clusters that may become disruptive, including symptoms related to physical discomfort or signs of systemic imbalance.

“Amlodipine is generally used to help manage persistent cardiovascular conditions that require ongoing symptomatic support.”

When used for hypertension, this medication contributes to easing the overall symptom load associated with chronic vascular conditions. For those experiencing chest pain, Amlodipine supports patients during episodes of heightened discomfort and helps ease the overall symptom burden. In the context of CAD, its use assists with maintaining functional stability and is relevant for easing challenging symptoms in patients with documented CAD.

Quick Fact: Relief for Angina Episodes
Amlodipine is relevant for easing symptoms of both stable angina and vasospastic angina.

Eligibility and Restrictions for Use

Who Can and Cannot Use Duactin?

The official regulatory profile for Duactin defines precise eligibility and contraindication rules for patient populations, strictly based on government-approved labeling.

Absolute Exclusion Duactin is contraindicated for use in patients with known hypersensitivity to the drug, any dihydropyridine class derivatives, or its excipients. Use is also strictly prohibited in patients experiencing severe hypotension, shock (including cardiogenic shock), or those with left ventricular outflow tract obstruction, such as high-grade aortic stenosis. Contraindication further applies to patients with haemodynamically unstable heart failure after acute myocardial infarction.

Age and Organ Status The medicine is approved for adults across all labeled uses and is conditionally established for pediatric patients aged 6 to 17 years for hypertension only. Safety and efficacy have not been established in children younger than 6 years. Patients with hepatic impairment require caution due to decreased clearance, while the normal dosage is recommended for those with renal impairment.

Reproductive Status Use during pregnancy is generally not recommended unless the potential benefit explicitly justifies the fetal risk, as safety has not been established. During lactation, a regulatory decision is required to discontinue either the medicine or nursing, reflecting the drug’s excretion into human milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Duactin (dactinomycin) has a comprehensive interaction profile, documented by regulatory agencies, that requires careful consideration when used with other medicinal products. The profile includes over 250 documented drug-drug interactions that are formally classified based on their potential clinical significance.

Interaction Classification Summary

The documented interactions are assigned a severity class to guide clinical risk management:

  • Major: These combinations are highly clinically significant and should generally be avoided, as the risk of the interaction outweighs the potential benefit.
  • Moderate: Combinations are moderately significant. They are usually avoided and should only be used under special circumstances with close monitoring.
  • Minor: These are minimally significant. Risks should be minimized, and an alternative drug or a monitoring plan should be considered.

Documented Interacting Substances

The most critical documented restrictions relate to the administration of Live Viral Vaccines and Anti-D (RHO) Immunoglobulin. Use with live viral vaccines is constrained by official labeling.

Duactin's interaction profile also involves specific constraints related to patient conditions, including myelosuppression and hepatic/renal toxicity.

Mechanism of Action

Selective Blockade of Arterial Calcium Channels

Duactin initiates its effect by acting as an inhibitor that selectively targets the L-type Voltage-Dependent Calcium Channels in the smooth muscle cells lining resistance arteries. This molecular interaction prevents the influx of extracellular calcium ions ( Ca^2+), which are essential for muscle contraction. The blockade is pronounced in highly active (depolarized) arteries, reflecting a voltage-dependent mechanism.

⬇️ The Mechanistic Cascade: From Cellular Relaxation to Systemic Effect

The resulting lack of intracellular calcium inhibits the signaling cascade responsible for muscle contraction, resulting in the relaxation and widening of arterial smooth muscle (vasodilation). This cellular event cascades into the systemic effect of lowering Total Peripheral Resistance (TPR) to blood flow. The lowering of this resistance represents a reduction of the afterload (the mechanical opposition to cardiac ejection).

⏳ Mechanism Kinetics and Sustained Modulation

Amlodipine's interaction with the calcium channel is characterized by a slow rate of binding and unbinding, which is critical for its extended duration of action. This kinetic profile supports a sustained effect on the modulation of vascular resistance. The slow onset is associated with a reduced incidence of reflex sympathetic activation (e.g., reflex tachycardia) compared to agents that produce rapid vasodilation.

Dosage and Administration Information

How to Use Duactin

Duactin (Amlodipine) is administered via the oral route only and is formulated for long-term therapeutic use. The medication is available as standard tablets and as a 1 mg/mL oral solution, supporting systemic absorption across all dosage strengths.


Official Dosing and Administration Patterns

The standard pattern for Duactin is once daily administration. Its long half-life supports a sustained therapeutic effect over a full 24-hour cycle. The dosage may be taken independently of meals.

Population Group Standard Initial Dose Maximum Daily Dose
Adults (Typical) 5 mg once daily 10 mg
Older Adults 2.5 mg once daily (considered) 10 mg
Hepatic Impairment 2.5 mg once daily (considered) 10 mg
Pediatric (6–17 yrs) 2.5 mg once daily 5 mg

Procedural Instructions

Dosage adjustments are typically performed over a gradual period, with an interval of 7 to 14 days recommended between titrations to allow the patient's response to the current dose to be fully assessed. Tablets are intended to be swallowed whole. If using the liquid form, precise measurement with a calibrated device is required to ensure the correct dose is administered. This medication is intended for a chronic, long-term use context to maintain continuous therapeutic support.

Recent Clinical Evidence

Research evidence / Overview of Studies for Duactin (Amlodipine)


Evidence for use in High Blood Pressure (Hypertension)

Research for Amlodipine in high blood pressure was evaluated in Randomized Controlled Trials (RCTs) and Systematic Reviews. These studies was evaluated in settings that measured changes in both resting and ambulatory blood pressure, which are outcomes monitoring physiological strain or stress. Long-term outcome trials studies explored Amlodipine's role within treatment regimens that monitored major clinical events, such as stroke, myocardial infarction, and cardiovascular death, over periods typically lasting four to five years.

Research highlights changes measured during the study period for blood pressure measurements. However, data for long-term outcome trials tracking event rates from Amlodipine monotherapy is more limited compared to data from combination therapy trials.


Evidence for use in Angina and Coronary Artery Disease (CAD)

Amlodipine was studied for chronic stable angina and vasospastic angina. For chronic stable angina, research includes randomized, placebo-controlled trials. These studies monitored outcomes related to functional imbalance, such as exercise duration, and evaluated in the number of episodic or acute changes reported by patients, such as the weekly frequency of anginal attacks.

In the context of Coronary Artery Disease (CAD), large RCTs research examined whether Amlodipine was associated with differences in the rate of certain pre-defined events, such as hospitalizations due to unstable angina and the need for coronary revascularization procedures.


What is Still Uncertain in the Research Landscape

Research examining Amlodipine's role in hypertension management was observed in large-scale, long-term studies. However, long-term effects are not fully established regarding the durability of outcomes related to physical discomfort (angina) when Amlodipine is used alone over many years. Also, most studies for angina were observed in settings focused on short-term symptom patterns, and follow-up durations were limited for tracking major hard cardiovascular events specifically in the angina-only population. The results apply only to the populations studied and reflect the specific conditions under which the research was conducted.

Key Studies & References

  1. Amlodipine - Drug Information (MedlinePlus)

Frequently Asked Questions (FAQ)

Common questions about Duactin (FAQ)


Q: How long does it typically take for a person to start noticing the intended effects of Duactin?

Official information indicates that the blood pressure lowering effect begins gradually, typically over a period of 4 to 8 hours after taking the medication. The maximum concentration of the drug in the bloodstream is usually reached between 6 to 8 hours after a dose. This slow and sustained release supports the medication’s intended long-term effect.


Q: Are there any common foods or drinks that should be avoided while taking Duactin?

Official documentation indicates a need for caution regarding certain food and drink choices. Consuming large amounts of grapefruit or grapefruit juice may increase the concentration of Duactin in the body, which could potentially worsen side effects. Additionally, alcohol may have additive effects in lowering blood pressure when taken with this medication.


Q: Is Duactin considered a high-risk medication in terms of side effects?

The official product label contains specific warnings and precautions for clinically significant risks, known as Boxed Warnings. These risks, such as tendon injury and peripheral neuropathy, necessitate careful monitoring by clinicians. The regulatory information specifies that these risks require careful professional attention.


Q: Does Duactin cause changes in energy levels or mood?

Official safety information lists changes in both energy and mood as documented adverse reactions. Tiredness, fatigue, and extreme sleepiness (somnolence) are noted as common effects. Changes in mood, including anxiety, depression, and confusion, are also documented in the regulatory profile.


Q: Does Duactin interact with common over-the-counter pain medications?

The regulatory profile for Duactin contains a large number of documented interactions with other substances. Regulatory safety information emphasizes the importance of informing a healthcare professional about all other medications being used, including any over-the-counter products, vitamins, or supplements.


Q: How long does Duactin stay in a person's system after the last dose?

Duactin is characterized by a long terminal elimination half-life, which refers to the time it takes for half of the drug to be removed from the body. This half-life is documented to be long, ranging from approximately 40 to 60 hours.


Q: Is it okay to take Duactin with vitamins or dietary supplements?

Official regulatory information advises caution when using herbal remedies and supplements. For example, St. John's Wort and multivitamins with minerals are noted to potentially affect how the drug works. The regulatory profile emphasizes that this usage should be reviewed by a healthcare professional.


Q: Why do some people experience dry mouth or blurred vision while on Duactin?

Dry mouth and visual disturbances, which may include blurred vision or double vision, are both documented in the official safety profiles of the medication. These are noted as uncommon adverse reactions.


Q: How does the body break down and eliminate Duactin?

Duactin is extensively broken down (metabolized) in the liver into inactive components. The resulting compounds are then slowly eliminated, mostly through the urine. The slow clearance rate is consistent with the drug's documented long half-life and its once-daily regimen.


Q: Does Duactin have any known interactions with herbal supplements like St. John's Wort?

Yes. Regulatory information indicates that St. John's Wort is thought to reduce the concentration and overall effect of this medication in the body. Official guidance emphasizes that usage of herbal products should be reviewed by a healthcare professional.


Q: What does the term 'contraindication' mean regarding Duactin?

A contraindication is an absolute exclusion, identifying a condition where use of the medication is generally prohibited. The regulatory label indicates that Duactin should not be used in patients who have certain conditions, such as a known hypersensitivity or severe conditions like cardiogenic shock.


Q: Are there any specific lifestyle factors mentioned in official documents that affect Duactin?

Official documents indicate that alcohol consumption may have additive effects in lowering blood pressure when taken concurrently with the medication.


Q: What happens if I stop taking Duactin suddenly?

Regulatory studies have shown that discontinuing the medication results in a slow, gradual return of blood pressure levels to their pretreatment baseline, typically over a period of 7 to 10 days. There is no documented evidence of a rebound effect following cessation.


Q: Can Duactin affect how I sleep?

Official safety information lists two potentially opposing effects related to sleep. Both insomnia (difficulty sleeping) and somnolence (extreme sleepiness or drowsiness) are documented in the list of adverse reactions.


Q: What is the difference between Duactin and other medications that treat the same condition?

Duactin (Amlodipine) possesses an exceptionally long half-life. This characteristic supports a sustained duration of action and is the basis for its once-daily dosing regimen and continuous modulation of vascular resistance.


Q: Do studies show a difference in how Duactin affects men versus women?

While no difference in dosing is currently suggested, regulatory data analysis shows that peripheral edema (swelling of the ankles or legs) may occur more commonly in women. Some studies have also shown differences in blood pressure response between men and women.


Q: Is it true that Duactin can be affected by grapefruit or grapefruit juice?

Yes. Official documents indicate that consuming large amounts of grapefruit or grapefruit juice can increase the drug's concentration in the body. This rise in concentration may lead to an increased risk of side effects.


Q: Is it safe to drive or operate machinery while taking Duactin?

Official product information states that the drug may have a minor to moderate influence on the ability to drive or operate complex machinery. The regulatory label advises that caution may be necessary, especially when treatment is initiated, or if side effects such as dizziness, headache, or fatigue are experienced.


Q: How quickly do the unwanted effects of Duactin usually go away after stopping the medicine?

The drug has a long half-life. After the medication is stopped, the physiological effects, such as blood pressure changes, slowly return to the pretreatment baseline over a number of days. The resolution of any associated unwanted effects would therefore align with this gradual clearance.


Q: What should a patient do if a dose of Duactin is missed?

Official guidance for administration details specific protocols for managing a missed dose. These protocols define the recommended time window for taking a dose and specify that a double dose should never be taken. Full instructions are available in the patient information leaflet.


Q: Are there certain ethnic groups that may respond differently to Duactin?

Studies indicate that the blood pressure response to this medication may vary based on ethnic groups. Specifically, research suggests that response among African-American men and women may be influenced by certain genetic factors.


Q: How long after stopping Duactin are potential drug interactions still a concern?

Due to the medication's long terminal elimination half-life, documented as 40 to 60 hours, it takes several days for the drug to be fully cleared from the body. Therefore, potential interactions with newly introduced medications may be a concern during that clearance period.


Q: What is the physical appearance of the Duactin tablet or capsule?

According to regulatory product listings, Duactin tablets are typically described by their shape (often round), their color (usually white to off-white), and a unique imprint code that allows them to be identified by their dosage strength.

How should Duactin be stored and disposed of?

How to Store and Dispose of Duactin (Amlodipine)

The official labeling mandates specific conditions for storing Duactin (Amlodipine) to preserve its stability and effectiveness, as well as strict protocols for disposal.


Storage Requirements

Duactin must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F), with permitted variations up to 30 C. The medicine must be kept in the tightly closed original container and protected from light, excess heat, and moisture. It is explicitly required to keep Duactin out of the sight and reach of children, and safety caps must always be secured.

Disposal Instructions

Unused or expired Duactin tablets should not be flushed down the toilet. The preferred method for disposal is through an authorized drug take-back program (e.g., kiosks or mail-back). If this is not an option, the medicine must be mixed with an undesirable substance (such as dirt or cat litter) in a sealed bag before being thrown into the household trash, in accordance with regulatory guidelines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Duactin found in:

A-Z Index: